Trial Profile

A Phase II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Tazemetostat in Combination With HMPL-689 in Patients With Relapsed/Refractory Lymphoma

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 24 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Amdizalisib (Primary) ; Tazemetostat (Primary)
Indications Diffuse large B cell lymphoma; Follicular lymphoma; Lymphoma; Mantle-cell lymphoma; Peripheral T-cell lymphoma
Focus Adverse reactions; Therapeutic Use
Sponsors HUTCHMED

Most Recent Events

22 Jan 2025 Status changed from recruiting to completed.
17 May 2024 According to a HUTCHMED media release, data from this study will be presented at the upcoming European Hematology Association (EHA) Hybrid Congress, taking place on June 13-16, 2024 in Madrid, Spain and online.
12 Sep 2023 According to a HUTCHMED media release, the first patient was dosed in February 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com